|Audit||Governance and Nominating||Compensation|
|Dr. David J. Mazzo|
Non Executive Chairman
Dr. Mazzo is the Chief Executive Officer and a Director at Caladrius Biosciences. Prior to joining Caladrius (formerly NeoStem), Dr. Mazzo served as Chief Executive Officer and as Director of Regado Biosciences, a company focused on the development of novel anti-thrombotic drug systems for acute and sub-acute cardiovascular indications. Dr.Mazzo was also Chief Executive Officer and Director of Aeterna Zentaris, Inc. and Chief Executive Officer and Director at Chugai Pharma USA LLC,a biopharmaceutical company. Dr. Mazzo has also held senior management and executive positions in research and development and was a Director of the Essex Chimie European subsidiary at Schering-Plough Corporation. Dr.Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr.Mazzo received his M.S. in Chemistry and his Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst.
|Mr. Douglas Godshall|
|Mr. Michael W. Rogers|